(Q24239831)

26 October 2023

Muki Shey

1

Muki

Shey

1 reference

26 October 2023

2

Eugene J Kongnyuy

Eugene J

Kongnyuy

1 reference

26 October 2023

Judith Shang

3

Judith

Shang

1 reference

19588374

Cochrane Database of Systematic Reviews

26 October 2023

language of work or name

1 reference

8 July 2009

0 references

published in

0 references

cites work

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Highly active antiretroviral therapy in Brazil: the challenge of universal access in a context of social inequality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Abacavir hypersensitivity reaction: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Antiretroviral treatment in resource-poor settings: the Brazilian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Potential factors affecting adherence with HIV therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005481.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD005481.PUB2

0 references

Fatcat ID

release_puyvfcmj3ra3ha2z6y7w5jufxa

0 references